Two months after the end of treatment, her brain metastases progressed regardless of the shrinkage of the primary renal tumor and pleural metastases. She underwent nivolumab and ipilimumab combination treatment was initiated, however, it was discontinued because of an immune-related adverse event. Overview of the CaseĪ woman of 68 years who had dyspnea was diagnosed with left renal cell carcinoma with multiple brain and pleural metastases. In this study, researchers reported a case of CR of brain metastases in a patient with mRCC, who was treated with axitinib after treatment failure with nivolumab and ipilimumab. Since complete remission is rare in patients with mRCC, sometimes despite systemic therapy, early detection of it and the development of an effective treatment strategy could be life-saving. It’s also only done for improving clinical symptoms. However, these treatments couldn’t show efficacy in brain metastasis, which is known to have a poor prognosis.įurthermore, brain metastasis is mainly treated with radiation therapy or neurosurgery. It’s often brought by tyrosine kinase inhibitor monotherapy in patients with metastatic renal cell carcinoma.įor metastatic renal cell carcinoma (mRCC) patients, the case of brain metastasis has been increasing despite advances in treatment that have prolonged survival.Ī vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) and an immune checkpoint inhibitor (ICI) have been reported to be beneficial in patients with mRCC. Cases of complete remission of cancers with brain metastases are very rare.
0 Comments
Leave a Reply. |